share_log

4: Statement of changes in beneficial ownership of securities-Officer Bligh James

4: Statement of changes in beneficial ownership of securities-Officer Bligh James

4:持股變動聲明-高管 Bligh James
美股SEC公告 ·  11/20 16:33

Moomoo AI 已提取核心訊息

Interim CFO of Conduit Pharmaceuticals, Bligh James, has engaged in a transaction involving the company's stock on November 18, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Bligh James, but without further information, the impact on his total number of shares held after the action cannot be determined.
Interim CFO of Conduit Pharmaceuticals, Bligh James, has engaged in a transaction involving the company's stock on November 18, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Bligh James, but without further information, the impact on his total number of shares held after the action cannot be determined.
Conduit Pharmaceuticals的臨時首席財務官Bligh James已於2024年11月18日參與了一筆涉及公司股票的交易。 交易的具體細節,包括股份數量、股票性質、交易價格和股份總價值,在公告中沒有披露。 這一舉動反映了Bligh James持股的變化,但在沒有進一步信息的情況下,無法確定該行動後他持有的股份數量。
Conduit Pharmaceuticals的臨時首席財務官Bligh James已於2024年11月18日參與了一筆涉及公司股票的交易。 交易的具體細節,包括股份數量、股票性質、交易價格和股份總價值,在公告中沒有披露。 這一舉動反映了Bligh James持股的變化,但在沒有進一步信息的情況下,無法確定該行動後他持有的股份數量。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息